drugset / Trial / NCT01994473
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
RandomizedSingle-groupSingle-blindTreatment
Summary
This is a study designed to evaluate the safety, tolerability, and PK of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia.
Timeline
- Start
- 2013-10
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulotaront | Small molecule | 10 ug | Oral |
| Subject | Ulotaront | Small molecule | 25 ug | Oral |
| Subject | Ulotaront | Small molecule | 50 ug | Oral |
| Subject | Ulotaront | Small molecule | 100 ug | Oral |
| Subject | Ulotaront | Small molecule | 75 mg | Oral |